PG
FOLD

PEAK6 Group’s Amicus Therapeutics FOLD Stock Holding History

PEAK6 Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,000
Closed -$168K – 4912
2015
Q3 		$168K Buy
+12,000
New +$188K ﹤0.01% 3889

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

PEAK6 Group's FOLD Position: Q4 2015 in Review

PEAK6 Group sold out of Amicus Therapeutics (FOLD) in Q4 2015, closing a stake of 12,000 shares — an estimated $168K sold.

PEAK6 Group first reported a position in FOLD in Q3 2015 and held it in 1 quarter. The position peaked at $168K in Q3 2015. 139 funds tracked by Wall St. Rank hold FOLD as of Q4 2015.

  • PEAK6 Group reported no remaining Amicus Therapeutics position as of Q4 2015 after selling out during the quarter.
  • PEAK6 Group sold 12,000 Amicus Therapeutics shares in Q4 2015, an estimated $168K.
  • PEAK6 Group first reported a position in Amicus Therapeutics in Q3 2015 and held it in 1 quarter.
  • PEAK6 Group's Amicus Therapeutics position peaked at $168K in Q3 2015.
  • 139 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.